Xeltis announced today that three pediatric patients have been successfully implanted with the world’s first heart valve enabling cardiovascular restoration. The children have been enrolled in the “Xplore-I” clinical study of Xeltis’ bioabsorbable pulmonary heart valve, a multi-centered feasibility trial currently enrolling pediatric patients from 2 to 21 years of age in leading heart centers in Europe.

“Initiating the clinical trial on our first bioabsorbable heart valve is a pivotal event for Xeltis. The extensive number of presentations on our technology at this year’s EACTS meeting confirms our company’s fast advancement,” stated Laurent Grandidier, Xeltis CEO, “We are reinventing the heart valve with the goal of making better solutions available to patients.”

View the full press release here.

Click here for a video about how the Xeltis restoring technology works.